A Randomized, Double-blind, Placebo-controlled Phase II Multi-Center Evaluation to Assess the Safety and Tolerability of DM199 Administered Intravenously and Subcutaneously in Subjects With Acute Ischemic Stroke

Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase II Multi-Center Evaluation to Assess the Safety and Tolerability of DM199 Administered Intravenously and Subcutaneously in Subjects With Acute Ischemic Stroke

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs DM 199 (Primary) ; DM 199 (Primary)
  • Indications Stroke
  • Focus Adverse reactions
  • Acronyms REMEDY
  • Sponsors DiaMedica Therapeutics
  • Most Recent Events

    • 22 Feb 2018 According to a DiaMedica Therapeutics media release, first patient has been enrolled at the Royal Melbourne Hospital, Melbourne Australia.
    • 18 Jan 2018 Status changed from not yet recruiting to recruiting in the fall of 2017, according to a DiaMedica Therapeutics media release.
    • 18 Jan 2018 According to a DiaMedica Therapeutics media release, patient enrollment is anticipated in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top